1. Phylogeny  
   GRK5 is a member of the G protein-coupled receptor kinase (GRK) family of serine/threonine kinases that evolved to regulate signal transduction by phosphorylating activated G protein-coupled receptors (GPCRs). Within the kinome, GRK5 belongs to the GRK4 subfamily along with GRK4 and GRK6, a grouping that is conserved throughout vertebrate evolution and is widely expressed in mammalian tissues such as heart, brain, and hematopoietic cells (willets2003nonvisualgrksare pages 1-2, sato2015theevolvingimpact pages 2-3). Phylogenetic studies indicate that the GRK family shares a common ancestry with other members of the AGC kinase superfamily. GRK5 can be traced back to early metazoans, and its orthologs have been identified across diverse species, reflecting the essential and conserved role of GRK-mediated receptor desensitization in eukaryotic signal transduction (mushegian2012theoriginand pages 11-11, willets2003nonvisualgrksare pages 1-2). Its evolutionary heritage suggests that the domain organization and catalytic features present in GRK5 are core elements retained from a common ancestor that facilitated the expansion of GPCR regulatory mechanisms (sato2015theevolvingimpact pages 2-3).
2. Reaction Catalyzed  
   GRK5 catalyzes the transfer of a phosphate group from ATP to specific serine and threonine residues on activated GPCR substrates. The overall chemical reaction can be written as follows:  
     ATP + [protein]–OH (serine/threonine) → ADP + [protein]–O–PO3^2– + H^+  
   This phosphorylation reaction is initiated when GRK5 recognizes an agonist‐bound receptor, thereby promoting the recruitment of beta-arrestins and triggering receptor desensitization, internalization, and downstream signaling events (homan2015crystalstructureof pages 1-2, sato2015theevolvingimpact pages 2-3).
3. Cofactor Requirements  
   The catalytic activity of GRK5 depends on the presence of divalent cations. Consistent with many serine/threonine kinases, GRK5 requires Mg²⁺ as a crucial cofactor to coordinate the phosphate group of ATP during the phosphorylation reaction (ord2005theregulationof pages 33-36, tutunea2016signaltransductionmechanisms pages 33-38).
4. Substrate Specificity  
   GRK5 exhibits a distinct substrate specificity that allows it to preferentially phosphorylate activated GPCRs. Its substrate recognition is generally determined by the active receptor conformation, leading to phosphorylation of serine and threonine residues located on the receptor’s C-terminal tail and/or third intracellular loop. GRK5 phosphorylates a wide variety of GPCRs including adrenergic receptors, Gi-coupled muscarinic acetylcholine receptors (notably the M2 and M4 subtypes), dopamine receptors, and opioid receptors (homan2015crystalstructureof pages 1-2, sato2015theevolvingimpact pages 2-3). In addition, GRK5 can target non-receptor substrates such as the heat shock protein–interacting protein (ST13), the tumor suppressor TP53/p53, histone deacetylase 5 (HDAC5), and arrestin-1 (ARRB1). Phosphorylation of ARRB1 by GRK5 leads to inhibition of G-protein–independent MAPK1/MAPK3 signaling downstream of 5HT4 receptors, whereas phosphorylation of HDAC5 causes its nuclear export and derepression of myocyte enhancer factor 2 (MEF2)–mediated transcription. Furthermore, TP53 phosphorylation by GRK5 inhibits its ability to induce apoptosis (homan2015crystalstructureof pages 1-2, sato2015theevolvingimpact pages 15-16).
5. Structure  
   GRK5 is characterized by a modular architecture that underpins its catalytic and regulatory functions. It contains an N-terminal region that comprises receptor and lipid interaction sites, including a phosphatidylinositol 4,5-bisphosphate (PIP2) binding site, which contributes to its constitutive plasma membrane association. A central catalytic kinase domain, which shares structural similarities with other AGC kinases such as protein kinase A (PKA), is inserted into a regulator of G protein signaling (RGS) homology domain. This dual arrangement is critical for substrate recognition and the phosphorylation of activated GPCRs (homan2015crystalstructureof pages 1-2, willets2003nonvisualgrksare pages 3-4).  
   At the C-terminus, GRK5 possesses an amphipathic helix that further facilitates membrane binding in the absence of classical palmitoylation sites. This unique region cooperates with adjacent basic residues to secure the kinase at the plasma membrane, thereby orienting the catalytic core toward receptor substrates (sato2015theevolvingimpact pages 3-4, willets2003nonvisualgrksare pages 3-4). In addition, GRK5 contains nuclear localization signals that enable its translocation to the nucleus, where it can phosphorylate nuclear targets such as HDAC5 (sato2015theevolvingimpact pages 15-16, homan2015crystalstructureof pages 10-11). Structural studies, including a 2.4 Å crystal structure of GRK5 in complex with a rationally designed inhibitor, have highlighted key features such as the positions of the activation loop, the hydrophobic spine, and the conserved catalytic motifs that are essential for its function (homan2015crystalstructureof pages 1-2, he2017molecularassemblyof pages 19-20).
6. Regulation  
   GRK5 is subject to complex regulatory mechanisms that modulate its localization, catalytic activity, and substrate specificity. Membrane association is fundamental to GRK5 function and is primarily mediated through its C-terminal amphipathic helix and N-terminal PIP2 binding site, which together ensure a robust interaction with plasma membrane phospholipids (willets2003nonvisualgrksare pages 5-7, sato2015theevolvingimpact pages 5-6). Calmodulin binding is also a critical regulatory mechanism for GRK5; binding of Ca²⁺–calmodulin to regions within the N-terminal and C-terminal domains can inhibit receptor and phospholipid binding, thereby modulating kinase activity and promoting the enzyme’s autophosphorylation (sedaghat2009delineationofthe pages 58-62, sato2015theevolvingimpact pages 15-16). In addition, phosphorylation by protein kinase C (PKC) has been reported to decrease GRK5 activity by affecting its membrane association and catalytic function (ord2005theregulationof pages 33-36, sedaghat2009delineationofthe pages 62-66). GRK5 autophosphorylation further regulates its substrate affinity and may alter its interaction with other signaling proteins. Moreover, GRK5 undergoes nucleocytoplasmic shuttling, which is regulated by its nuclear localization signals; this controlled translocation permits GRK5 to phosphorylate both membrane-associated GPCR substrates and nuclear targets, such as HDAC5 and p53 (sato2015theevolvingimpact pages 15-16, homan2015crystalstructureof pages 10-11). Finally, rationally designed small-molecule inhibitors, such as CCG215022, have been developed to target GRK5, exploiting its unique structural features for potential therapeutic applications (homan2015crystalstructureof pages 1-2, pfleger2019gproteincoupledreceptor pages 8-9).
7. Function  
   GRK5 plays a central role in the regulation of GPCR signaling by catalyzing the phosphorylation of activated receptors. This phosphorylation event is critical for the recruitment of beta-arrestins, which not only uncouple receptors from heterotrimeric G proteins but also promote receptor internalization and trigger downstream, arrestin-mediated signaling cascades (homan2015crystalstructureof pages 1-2, sato2015theevolvingimpact pages 2-3). In addition to its canonical role in GPCR desensitization, GRK5 phosphorylates a variety of non-receptor substrates. For instance, phosphorylation of HDAC5 by GRK5 results in the nuclear export of this transcriptional repressor, thereby allowing MEF2-mediated gene transcription, a process that is particularly important in cardiac myocyte gene expression and hypertrophic signaling (sato2015theevolvingimpact pages 15-16, homan2015crystalstructureof pages 1-2). GRK5 also phosphorylates TP53/p53, thereby attenuating p53-mediated apoptotic signals, which may have implications in tumor suppression and cell cycle regulation, and ARRB1, where its phosphorylation inhibits downstream MAPK1/MAPK3 signaling from 5HT4 receptors (homan2015crystalstructureof pages 1-2).  
   Expression of GRK5 is robust in cardiac tissue, where it contributes to the regulation of beta-adrenergic receptor signaling and is implicated in the pathogenesis of heart failure. Its activity in modulating receptor responsiveness is essential for maintaining cellular homeostasis and adapting to changes in extracellular stimuli. GRK5 is also expressed in other tissues, where it participates in diverse signaling pathways by regulating the extent and duration of GPCR-mediated signals (pfleger2019gproteincoupledreceptor pages 1-2, sato2015theevolvingimpact pages 15-16). Its dual localization at the plasma membrane and the nucleus further expands its functional repertoire to include roles in transcriptional regulation and cellular stress responses.
8. Other Comments  
   Recent structural studies have led to the development of selective inhibitors for GRK5. A rationally designed compound, CCG215022, has been shown to exhibit nanomolar potency against GRK5 and GRK2, highlighting the potential for therapeutic modulation of GRK5 in disease contexts (homan2015crystalstructureof pages 1-2). GRK5 is associated with several pathological conditions, particularly in cardiovascular disease; alterations in GRK5 expression or activity have been linked to heart failure and pathological hypertrophy due to dysregulated beta-adrenergic receptor desensitization (pfleger2019gproteincoupledreceptor pages 8-9, sato2015theevolvingimpact pages 15-16). In addition, phosphorylation of non-receptor substrates such as p53 has implications in oncogenesis by influencing apoptotic pathways (information section). Endogenous regulatory mechanisms, including calmodulin binding and PKC-mediated phosphorylation, are integral in modulating GRK5 activity and may serve as additional targets for drug discovery. Although specific inhibitors of GRK5 remain under active investigation, the understanding of its structural organization and regulatory mechanisms has provided a foundation for the future development of more selective therapeutic agents (homan2015crystalstructureof pages 1-2, willets2003nonvisualgrksare pages 5-7).
9. References
10. homan2015crystalstructureof pages 1-2
11. homan2015crystalstructureof pages 10-11
12. sato2015theevolvingimpact pages 2-3
13. sato2015theevolvingimpact pages 15-16
14. ord2005theregulationof pages 33-36
15. tutunea2016signaltransductionmechanisms pages 33-38
16. willets2003nonvisualgrksare pages 1-2
17. mushegian2012theoriginand pages 11-11
18. pfleger2019gproteincoupledreceptor pages 1-2
19. pfleger2019gproteincoupledreceptor pages 8-9
20. sedaghat2009delineationofthe pages 58-62
21. sedaghat2009delineationofthe pages 62-66
22. he2017molecularassemblyof pages 19-20
23. baameur2009identificationofa pages 22-26
24. sato2015theevolvingimpact pages 3-4
25. willets2003nonvisualgrksare pages 5-7
26. sato2015theevolvingimpact pages 15-15
27. sato2015theevolvingimpact pages 16-18
28. sedaghat2009delineationofthe pages 66-70
29. todd2021theroleof pages 29-33

References

1. (homan2015crystalstructureof pages 1-2): K. Homan, Helen V. Waldschmidt, A. Glukhova, A. Cannavo, Jianliang Song, J. Cheung, W. Koch, S. Larsen, and J. Tesmer. Crystal structure of g protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor\*♦. The Journal of Biological Chemistry, 290:20649-20659, Jun 2015. URL: https://doi.org/10.1074/jbc.m115.647370, doi:10.1074/jbc.m115.647370. This article has 59 citations.
2. (homan2015crystalstructureof pages 10-11): K. Homan, Helen V. Waldschmidt, A. Glukhova, A. Cannavo, Jianliang Song, J. Cheung, W. Koch, S. Larsen, and J. Tesmer. Crystal structure of g protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor\*♦. The Journal of Biological Chemistry, 290:20649-20659, Jun 2015. URL: https://doi.org/10.1074/jbc.m115.647370, doi:10.1074/jbc.m115.647370. This article has 59 citations.
3. (sato2015theevolvingimpact pages 15-16): Priscila Y. Sato, J. Kurt Chuprun, Mathew Schwartz, and Walter J. Koch. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiological Reviews, 95:377-404, Apr 2015. URL: https://doi.org/10.1152/physrev.00015.2014, doi:10.1152/physrev.00015.2014. This article has 184 citations and is from a highest quality peer-reviewed journal.
4. (tutunea2016signaltransductionmechanisms pages 33-38): E Tutunea. Signal transduction mechanisms mediating the regulation of vascular g protein-coupled receptors. Unknown journal, 2016.
5. (baameur2009identificationofa pages 22-26): F Baameur. Identification of a conserved cluster in the rh domain of grk critical for activation by gpcrs. Unknown journal, 2009.
6. (he2017molecularassemblyof pages 19-20): Yuanzheng He, Xiang Gao, Devrishi Goswami, Li Hou, Kuntal Pal, Yanting Yin, Gongpu Zhao, Oliver P Ernst, Patrick Griffin, Karsten Melcher, and H Eric Xu. Molecular assembly of rhodopsin with g protein-coupled receptor kinases. Cell Research, 27:728-747, May 2017. URL: https://doi.org/10.1038/cr.2017.72, doi:10.1038/cr.2017.72. This article has 57 citations and is from a domain leading peer-reviewed journal.
7. (pfleger2019gproteincoupledreceptor pages 8-9): Jessica Pfleger, Kenneth Gresham, and Walter J. Koch. G protein-coupled receptor kinases as therapeutic targets in the heart. Nature Reviews Cardiology, 16:612-622, Jun 2019. URL: https://doi.org/10.1038/s41569-019-0220-3, doi:10.1038/s41569-019-0220-3. This article has 155 citations and is from a domain leading peer-reviewed journal.
8. (sato2015theevolvingimpact pages 15-15): Priscila Y. Sato, J. Kurt Chuprun, Mathew Schwartz, and Walter J. Koch. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiological Reviews, 95:377-404, Apr 2015. URL: https://doi.org/10.1152/physrev.00015.2014, doi:10.1152/physrev.00015.2014. This article has 184 citations and is from a highest quality peer-reviewed journal.
9. (sato2015theevolvingimpact pages 16-18): Priscila Y. Sato, J. Kurt Chuprun, Mathew Schwartz, and Walter J. Koch. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiological Reviews, 95:377-404, Apr 2015. URL: https://doi.org/10.1152/physrev.00015.2014, doi:10.1152/physrev.00015.2014. This article has 184 citations and is from a highest quality peer-reviewed journal.
10. (sato2015theevolvingimpact pages 2-3): Priscila Y. Sato, J. Kurt Chuprun, Mathew Schwartz, and Walter J. Koch. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiological Reviews, 95:377-404, Apr 2015. URL: https://doi.org/10.1152/physrev.00015.2014, doi:10.1152/physrev.00015.2014. This article has 184 citations and is from a highest quality peer-reviewed journal.
11. (sato2015theevolvingimpact pages 3-4): Priscila Y. Sato, J. Kurt Chuprun, Mathew Schwartz, and Walter J. Koch. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiological Reviews, 95:377-404, Apr 2015. URL: https://doi.org/10.1152/physrev.00015.2014, doi:10.1152/physrev.00015.2014. This article has 184 citations and is from a highest quality peer-reviewed journal.
12. (sato2015theevolvingimpact pages 5-6): Priscila Y. Sato, J. Kurt Chuprun, Mathew Schwartz, and Walter J. Koch. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiological Reviews, 95:377-404, Apr 2015. URL: https://doi.org/10.1152/physrev.00015.2014, doi:10.1152/physrev.00015.2014. This article has 184 citations and is from a highest quality peer-reviewed journal.
13. (sedaghat2009delineationofthe pages 58-62): K Sedaghat. Delineation of the molecular mechanisms underlying the regulation of d1 dopaminergic receptor by g protein-coupled receptor kinase 2 and 3. Unknown journal, 2009.
14. (sedaghat2009delineationofthe pages 66-70): K Sedaghat. Delineation of the molecular mechanisms underlying the regulation of d1 dopaminergic receptor by g protein-coupled receptor kinase 2 and 3. Unknown journal, 2009.
15. (todd2021theroleof pages 29-33): NK Todd. The role of g protein-coupled receptor kinases in modulating γ-secretase activity andamyloid-β generation. Unknown journal, 2021.
16. (willets2003nonvisualgrksare pages 1-2): Jonathon M. Willets, R.A.John Challiss, and Stefan R. Nahorski. Non-visual grks: are we seeing the whole picture? Trends in Pharmacological Sciences, 24:626-633, Dec 2003. URL: https://doi.org/10.1016/j.tips.2003.10.003, doi:10.1016/j.tips.2003.10.003. This article has 162 citations and is from a highest quality peer-reviewed journal.
17. (willets2003nonvisualgrksare pages 3-4): Jonathon M. Willets, R.A.John Challiss, and Stefan R. Nahorski. Non-visual grks: are we seeing the whole picture? Trends in Pharmacological Sciences, 24:626-633, Dec 2003. URL: https://doi.org/10.1016/j.tips.2003.10.003, doi:10.1016/j.tips.2003.10.003. This article has 162 citations and is from a highest quality peer-reviewed journal.
18. (willets2003nonvisualgrksare pages 5-7): Jonathon M. Willets, R.A.John Challiss, and Stefan R. Nahorski. Non-visual grks: are we seeing the whole picture? Trends in Pharmacological Sciences, 24:626-633, Dec 2003. URL: https://doi.org/10.1016/j.tips.2003.10.003, doi:10.1016/j.tips.2003.10.003. This article has 162 citations and is from a highest quality peer-reviewed journal.
19. (mushegian2012theoriginand pages 11-11): A. Mushegian, V. Gurevich, and E. Gurevich. The origin and evolution of g protein-coupled receptor kinases. PLoS ONE, Mar 2012. URL: https://doi.org/10.1371/journal.pone.0033806, doi:10.1371/journal.pone.0033806. This article has 94 citations and is from a peer-reviewed journal.
20. (ord2005theregulationof pages 33-36): FU Ord. The regulation of the human sphingosine 1-phosphate receptor, s1p 3. Unknown journal, 2005.
21. (pfleger2019gproteincoupledreceptor pages 1-2): Jessica Pfleger, Kenneth Gresham, and Walter J. Koch. G protein-coupled receptor kinases as therapeutic targets in the heart. Nature Reviews Cardiology, 16:612-622, Jun 2019. URL: https://doi.org/10.1038/s41569-019-0220-3, doi:10.1038/s41569-019-0220-3. This article has 155 citations and is from a domain leading peer-reviewed journal.
22. (sedaghat2009delineationofthe pages 62-66): K Sedaghat. Delineation of the molecular mechanisms underlying the regulation of d1 dopaminergic receptor by g protein-coupled receptor kinase 2 and 3. Unknown journal, 2009.